

1 **Article Type:**

2 Original research

3  
4 **Title:**

5 Skeletal muscle angiogenic, regulatory and heat shock protein responses to prolonged passive  
6 hyperthermia of the human lower limb

7  
8 **Short Title:**

9 Skeletal muscle responses to passive limb hyperthermia

10

11 **Authors:**

12 Oliver R. Gibson<sup>1,2,3</sup>, Rónan Astin<sup>4</sup>, Zudin Puthuchear<sup>5</sup>, Shreya Yadav<sup>6,7</sup>, Sophie Preston<sup>6,7</sup>, Felicity  
13 N.E. Gavins<sup>6,7</sup>, José González-Alonso<sup>1,3</sup>

14

15 **Author Affiliations**

16 <sup>1</sup> Centre for Human Performance, Exercise and Rehabilitation (CHPER), Brunel University London,  
17 UK.

18 <sup>2</sup> Centre for Physical Activity in Health and Disease (CHPAD), Brunel University London, UK.

19 <sup>3</sup> Division of Sport, Health and Exercise Sciences, Brunel University London, UK.

20 <sup>4</sup> Department of Medicine, Centre for Human Health and Performance, University College London,  
21 UK.

22 <sup>5</sup> Adult Critical Care Unit, Barts and The London School of Medicine and Dentistry, William Harvey  
23 Research Institute, Queen Mary University of London, UK.

24 <sup>6</sup> Centre for Inflammation Research and Translational Medicine (CIRTM), Brunel University London,  
25 UK

26 <sup>7</sup> Division of Biosciences, Brunel University London, UK.

27

28 **Corresponding Author Details:**

29 Dr Oliver R. Gibson, [oliver.gibson@brunel.ac.uk](mailto:oliver.gibson@brunel.ac.uk)

30 Centre for Human Performance, Exercise and Rehabilitation (CHPER), Centre for Physical Activity in  
31 Health and Disease (CHPAD)

32 Division of Sport, Health and Exercise Sciences, Department of Life Sciences

33 Brunel University London,

34 Uxbridge,

35 UB8 3PH,

36 United Kingdom

37

38 **Main text body word count**

39 5763

40

41 **Abstract word count**

42 244

43

44 **Number of illustrations**

45 Five figures, three tables.

46

47 **Key words**

48 Angiogenesis, Heat shock proteins, Heat therapy, Hyperthermia, Passive heating, Thermal therapy.

49 **Abstract**

50 Passive hyperthermia induces a range of physiological responses including augmenting skeletal  
51 muscle mRNA expression. This experiment aimed to examine gene and protein responses to  
52 prolonged passive leg hyperthermia. Seven young participants underwent 3 h of resting unilateral leg  
53 heating (HEAT) followed by a further 3 h of rest, with the contralateral leg serving as an unheated  
54 control (CONT). Muscle biopsies were taken at baseline (0 h), and 1.5, 3, 4, and 6 h in HEAT and 0  
55 and 6 h in CONT to assess changes in selected mRNA expression via qRT-PCR, and HSP72 and  
56 VEGF $\alpha$  concentration via ELISA. Muscle temperature ( $T_m$ ) increased in HEAT plateauing from 1.5 to  
57 3 h ( $+3.5\pm 1.5^\circ\text{C}$  from  $34.2\pm 1.2^\circ\text{C}$  baseline value;  $p<0.001$ ), returning to baseline at 6 h. No change  
58 occurred in CONT. eNOS, FOXO-1, Hsp72, and VEGF $\alpha$  mRNA increased in HEAT ( $p<0.05$ ) however  
59 post-hoc analysis identified that only Hsp72 mRNA statistically increased (at 4 h vs. baseline). When  
60 peak change during HEAT was calculated ANGPT-2 decreased ( $-0.4\pm 0.2$ -fold), and CCL2 ( $+2.9\pm 1.6$ -  
61 fold), FOXO-1 ( $+6.2\pm 4.4$ -fold), Hsp27 ( $+2.9\pm 1.7$ -fold), Hsp72 ( $+8.5\pm 3.5$ -fold), Hsp90 $\alpha$  ( $+4.6\pm 3.7$ -fold),  
62 and VEGF $\alpha$  ( $+5.9\pm 3.1$ -fold) increased from baseline (all  $p<0.05$ ). At 6 h  $T_m$  were not different between  
63 limbs ( $p=0.582$ ; CONT= $32.5\pm 1.6^\circ\text{C}$ , HEAT= $34.3\pm 1.2^\circ\text{C}$ ), and only ANGPT-2 ( $p=0.031$ ;  $-1.3\pm 1.4$ -fold)  
64 and VEGF $\alpha$  ( $p=0.030$ ;  $1.1\pm 1.2$ -fold) differed between HEAT and CONT. No change in VEGF $\alpha$  or  
65 HSP72 protein concentration were observed over time, however, peak change in VEGF $\alpha$  did increase  
66 ( $p<0.05$ ) in HEAT ( $+140\pm 184\text{ pg}\cdot\text{mL}^{-1}$ ) vs CONT ( $+7\pm 86\text{ pg}\cdot\text{mL}^{-1}$ ). Passive hyperthermia transiently  
67 augmented ANGPT-2, CCL2, eNOS, FOXO-1, Hsp27, Hsp72, Hsp90 $\alpha$  and VEGF $\alpha$  mRNA, and  
68 VEGF $\alpha$  protein.

69

70 **Introduction**

71 Physiological responses to passive heating have been subject to experimental interest to further  
72 understand applications and mechanisms associated with therapeutic hyperthermia (also described  
73 as thermal therapy or heat therapy)(1, 2). Several beneficial responses, apparently similar to exercise  
74 training(3) have been reported in a range of relevant health and disease contexts e.g., ameliorated  
75 metabolic status(4–8), improved cardiovascular risk factors(3, 9–16), and enhanced muscle  
76 function(8, 17–21). Given these positive outcomes, heat therapy has been proposed as an alternative  
77 or precursor to exercise training in those unwilling or unable to engage in physical activity(2, 22, 23).  
78 Different physiological responses occur in response to whole body vs regional heating(24–28).  
79 However, elevations in local or systemic temperature increase blood flow and shear stress facilitating  
80 micro- and macrovascular adaptation(1) and increased circulation of microvesicles(29). Concurrent  
81 with these adaptations are molecular responses.

82

83 To date passive heating has been demonstrated as a modifier of an abundance of direct angiogenic  
84 and metabolic regulatory genes(27, 28, 30), and heat shock proteins [HSP (protein), Hsp (gene)]  
85 which further facilitate or contribute to adaptation(1). HSPs are a family of multifunctional proteins  
86 classified by molecular weight which support correct protein function and are therefore considered  
87 important contributors for inducing desirable adaptations(2, 31). HSPs are located across multiple  
88 tissue sites targeted by heat therapy, including skeletal, cardiac, vascular smooth muscle, and the  
89 central nervous system(32). It has been shown that inducing hyperthermia in both limbs, or the thigh  
90 alone, for a period of 90 min, promotes the expression of angiogenic regulatory and Hsp genes in  
91 human skeletal muscle(28). In that study gene expression relative to the baseline sample was  
92 augmented 30 min post lower limb heating [VEGF $\alpha$ , CCL2, ANGPT2, Hsp27, Hsp72, and Hsp90 $\alpha$ ,  
93 see table 1 for further gene details](28). Although most changes had acquiesced 2 h post heating  
94 (except FOXO1 and CX3L1), these data support the efficacy of local passive heating as a tool for  
95 augmenting skeletal muscle gene expression. Using a similar experimental design, it has also been  
96 demonstrated that 1 h of whole-body, but not single leg hyperthermia, augments anabolic  
97 (Akt/mTOR), mitochondrial, and Hsp signalling(27). The lack of change in the single leg heating model  
98 opposes the previously discussed work(28), suggesting that a signalling threshold had not been  
99 surpassed. Physiological data collected in that study(27) identified that whole body heating increased  
100 muscle, skin, and core temperature, but single leg heating only increased local skin and muscle  
101 temperature. This points to a role of one of those factors in augmenting the magnitude of expression  
102 in a direct or indirect manner.

103

104 Interestingly from a methodological viewpoint, with serial timepoint sampling the peak change in  
105 mRNA can be calculated on an individual participant basis across an intervention(27). This highlights  
106 that individual variability in the time course of gene expression exists and emphasises that the time-

107 course of heating-induced gene response is incompletely understood. Further, though data are  
108 consistent in demonstrating a significant increase in Hsp mRNA expression, and protein accumulation  
109 in response to combined exercise-heat stress(33–39), the magnitude of Hsp response to passive  
110 heating (a more feasible clinical intervention) has also not been adequately described. Further to this,  
111 whilst acute and repeated passive hyperthermia of <90 min can increase angiogenic and/or HSP  
112 protein concentrations(17, 18, 40), whether prolonging local hyperthermia elicits a greater change  
113 has not been examined. Collectively these data point towards a need to further characterise the  
114 skeletal muscle gene expression response, and subsequent alterations in protein concentration  
115 following local hyperthermia with a view to further enhancing the understanding of the therapeutic  
116 potential of heat therapy interventions. Specifically, to determine whether a longer heating duration  
117 i.e., 3 h vs 1.5 h augments the timecourse and magnitude of transcriptional response, and whether  
118 the calculation of change differs depending on the timepoints utilised.

119

120 The aims of this experiment were to examine the time course of selected gene and protein responses  
121 to prolonged (3 h) local passive leg hyperthermia, and subsequent recovery (3 h) in comparison to an  
122 unheated leg. It was hypothesised that limb heating-induced local skeletal muscle hyperthermia,  
123 would activate the expression of angiogenic and regulatory genes, and increase heat shock protein  
124 expression, with minimal alterations in systemic or contralateral limb responses. Further to this it was  
125 hypothesised that a single bout of prolonged local skeletal muscle hyperthermia would increase  
126 VEGF $\alpha$  and HSP72 skeletal muscle protein concentration.

127 **Method**

128 Participants

129 Seven healthy participants (two females) participated in the study (age  $23 \pm 2$  yrs., height  $172.6 \pm 9.9$   
130 cm, mass  $76.2 \pm 13.3$  kg, BMI  $25.5 \pm 3.6$  kg.m<sup>2</sup>, whole limb volume  $9882 \pm 1373$  mL, lean limb volume  
131  $8768 \pm 920$  mL). All participants were non-smokers and free from known cardiorespiratory, metabolic,  
132 and neurological diseases. Participants arrived at the laboratory postprandial and euhydrated (urine  
133 osmolality  $<700$  mOsmol·kgH<sub>2</sub>O<sup>-1</sup>(41)). They were required to have abstained from strenuous  
134 exercise and alcohol intake for  $>48$  h and caffeine consumption for  $>12$  h. *A priori* power analysis  
135 using data from a similar study [protocol 3,(28)] and established statistical conventions ( $\alpha=0.05$ ,  
136  $\beta=0.8$ ) had identified that six participants would be required to determine pre-post heating differences  
137 between heating and control limbs (the primary research question). Written informed consent was  
138 obtained from the participants prior to the study. All procedures were approved by the Brunel  
139 University London Research Ethics Committee (7692-A-Feb/2018-11768-1) and conformed to the  
140 guidelines of the Declaration of Helsinki.

141

142 Experimental design

143 Participants attended one experimental visit which commenced at  $08.00 \pm 01.00$  a.m. and following  
144 instrumentation and a period of supine rest ( $\sim 0.5$  h), baseline measurements preceded a protocol  
145 involving 3 h of unilateral whole leg passive heating (HEAT) whilst the contralateral control leg  
146 remained unheated (CONT). The passive limb heating device has been described previously(26, 42,  
147 43), briefly a custom-built water-perfused trouser covered the entire leg, before being wrapped in foil  
148 blankets sealed with medical tape. The trouser was connected to a thermostatically controlled  
149 circulator (Julabo F-34; Seelbach) to allow a constant perfusion of  $50^{\circ}\text{C}$  water. Following removal of  
150 the passive heating stimulus, participants rested supine for a further 3 h. All measurements were  
151 taken every 0.5 h with a mean of a 60 s period recorded unless otherwise stated.

152

153 Experimental protocols

154 Upon arrival at the laboratory, participants voided, and stature and nude body mass were recorded  
155 whilst wearing shorts and a t-shirt (SECA model 798, Hamburg, Germany). To determine whole and  
156 lean limb volume the circumference of the heated limb was measured via an anthropometric tape  
157 measure at descending anatomical markers, with anterior and posterior skinfold thickness at the thigh,  
158 and medial and lateral skinfold thickness at the calf recorded using callipers (Harpenden, Burgess  
159 Hill, UK)(44). Following anthropometric measures, participants inserted a rectal thermistor to a  
160 marked depth of 15 cm (RET-1 Physitemp, USA) to measure core temperature ( $T_{\text{core}}$ ) and entered  
161 the environmental chamber (Procema, UK; maintained at  $21.6 \pm 1.4^{\circ}\text{C}$ ) positioning themselves supine  
162 on a custom bed for instrumentation. A 3-lead ECG (PowerLab 26T and LabChart 7, ADI Instruments,  
163 UK) was affixed to the participant and an infrared photoplethysmography arterial blood pressure

164 device cuff positioned on the arm and on the middle finger of the right hand (Finometer; FMS,  
165 Netherlands). Stroke volume (SV) was estimated using the ModelFlow method included with the  
166 Beatscope computer software package (Beatscope; FMS, Netherlands), with cardiac output ( $\dot{Q}$ )  
167 calculated following corrections for age, height, and mass (45). For measurement of intramuscular  
168 temperatures ( $T_m$ ), sterile implantable thermocouples (T-204f, PhysiTemp, USA) were inserted into  
169 the mid-portion of the vastus lateralis muscle of the heated and control leg using a 22-gauge catheter  
170 (BD Venflon; Becton-Dickson) at a depth of 2.5 cm. Skin surface temperature ( $T_{sk}$ ) of the heated and  
171 control limb was measured via thermocouples (IT-18, PhysiTemp, USA) affixed to the skin over the  
172 belly of the thigh ( $T_{thigh}$ ) and calf ( $T_{calf}$ ). Additionally,  $T_{sk}$  was measured at forehead ( $T_{head}$ ), over the  
173 belly of the right pectoralis major ( $T_{chest}$ ) and left triceps brachii ( $T_{arm}$ ) and on the dorsal surface of the  
174 left and right foot ( $T_{FOOT}$ ) using surface temperature loggers (Hygrochron iButton, USA) set to record  
175 data at 60 s intervals. Torso temperature ( $T_{torso}$ ) was calculated from an unweighted average of  $T_{head}$ ,  
176  $T_{chest}$ , and  $T_{arm}$ , leg skin temperature ( $T_{leg}$ ) was calculated from an unweighted average of  $T_{thigh}$ ,  $T_{calf}$ ,  
177 and  $T_{foot}$ . Thermocouples were connected to a thermocouple meter (TC-2000, Sable Systems, NV,  
178 USA) and collected at 1000 Hz using commercially available data acquisition and analysis systems  
179 (PowerLab 26T, AD Instruments, LabChart 7, AD Instruments). Breath by breath (Vyntus, Carefusion)  
180 collection of expired metabolic gases occurred for 5 min to quantify whole body oxygen uptake ( $\dot{V}O_2$ ),  
181 carbon dioxide production ( $\dot{V}CO_2$ ), minute ventilation ( $\dot{V}_E$ ), breathing frequency ( $F_b$ ), tidal volume ( $\dot{V}_T$ )  
182 and to facilitate the calculation of respiratory exchange ratios (RER). Perceptual responses included  
183 whole body thermal comfort (TCOMF) and thermal sensation (TSENS) determined on a five (from 1,  
184 comfortable, to 5, very uncomfortable) and seventeen (from 0.0, unbearably cold, to 8.0, unbearably  
185 hot) point scale respectively (46), and the rating of perceived exertion (RPE) measured using a 15-  
186 point Borg scale (from 6, very very light, to 20, very very hard) (47).

187

#### 188 Tissue and blood sampling, and analysis

189 A total of seven muscle biopsy samples were taken during the experiment, with five samples obtained  
190 from the heated limb (at 0, 1.5, 3, 4, and 6 h timepoints) and two samples obtained from the control  
191 limb (at 0 and 6 h). A contralateral comparison model was implemented to increase statistical power  
192 by reducing the amount of between-person variability and reduce the time, cost and discomfort  
193 associated with this invasive study (48). Skeletal muscle tissue was sampled from the vastus lateralis  
194 adjacent to the  $T_m$  site in sterile conditions under local anaesthetic (Xylocaine, 1%) using a 7 mm  
195 Bergström biopsy needle and manual suction (49). Following each biopsy, the incision was closed  
196 with steristrips and covered with a sterile dressing. For the 1.5 h sample the biopsy procedure was  
197 conducted through a custom opening in the water perfused trouser to minimize heat loss. Serial  
198 samples were obtained ~2 cm distally or proximally from one another. Following sampling, tissue was  
199 rinsed immediately in an ice cold 0.9% NaCl solution, and then immediately transferred to a 1.5 mL  
200 microtube and snap frozen in liquid nitrogen. Samples were then stored at  $-86^\circ\text{C}$  for later analysis.

201

202 For determination of selected gene transcript responses (table 1; ThermoFisher Scientific, UK), a ~30  
203 mg portion of the muscle sample was homogenized in 10  $\mu$ L of  $\beta$ -Mercaptoethanol and 1 mL of Buffer  
204 RLT Plus. The homogenate was subsequently analysed via qRT-PCR in duplicate with responses  
205 characterized against the chosen housekeeping gene glyceraldehyde-3-phosphate dehydrogenase  
206 (GAPDH) by a commercial analytical laboratory (NMI Natural and Medical Sciences at the University  
207 of Tübingen, Reutlingen, Germany). Total RNA was isolated using the RNeasy fibrous tissue Mini Kit  
208 (#74704; Qiagen) according to the manufacturer's recommendations. The samples were digested  
209 using the DNase provided prior to synthesis of cDNA. cDNA was synthesised in the presence of  
210 hexanucleotides in a reaction volume of 15  $\mu$ L using MMuLV reverse transcriptase (New England  
211 Biolabs #M0203L). To check for contamination by genomic DNA, for each sample a mock reaction  
212 lacking reverse transcriptase (-RT) was carried out. Samples then underwent a pre-amplification step  
213 (TaqMan™ PreAmpMaster Mix Kit). For the real-time PCR reaction, 1.25  $\mu$ L of cDNA were employed.  
214 HSP72 (CV=2.5%) and VEGF $\alpha$  (CV=13.2%) protein concentrations were determined at all timepoints  
215 using commercially available ELISA kits (ThermoFisher Scientific) and normalized per mg of total  
216 protein via the Bradford method (ThermoFisher Scientific). Due to insufficient tissue sample, the 4 h  
217 timepoint (all participants) and participant #7 was excluded from the VEGF $\alpha$  analysis. For this reason,  
218 other genes demonstrating a change over time e.g. eNOS and FOXO1 were not analysed with HSP72  
219 and VEGF $\alpha$  chosen given greater prominence in thermal and exercise literature pertaining to heat  
220 therapy(1) and angiogenesis (75).

221

222 \*\*\*INSERT TABLE 1 NEAR HERE PLEASE\*\*\*

223

224 Venous blood samples were taken at 0.5 h intervals via an 18-gauge cannula (BD Venflon; Becton-  
225 Dickson) inserted into a superficial antecubital vein of the arm. Blood draws of ~7 mL occurred at  
226 timepoints corresponding with muscle biopsy sampling (0, 1.5, 3, 4, 6 h), and ~2 mL in volume for all  
227 other time points. An equivalent volume 0.9% NaCl solution (BD PosiFlush; Becton-Dickson) was  
228 flushed through the cannula to maintain patency following each blood draw. Whole blood was  
229 immediately aliquoted to determine hematocrit (Hct), hemoglobin (Hb), and whole blood glucose [Glu]  
230 concentrations. Hct was determined by the packed cell volume method under a microscope after  
231 standard centrifugation of sodium-heparinized capillary tubes (microhematocrit tubes, HaematoSpin  
232 1400 centrifuge; Hawksley), a mean of quadruplicate samples was recorded. Blood [Hb] was obtained  
233 by photometric analysis (HemoCue Hb 201+ System; HemoCue), and [Glu] was determined at only  
234 0, 1.5, 3, 4 and 6 h (HemoCue Glucose 201+ System; HemoCue), for both [Hb] and [Glu] a mean of  
235 triplicate samples was recorded.

236

237 Statistical analysis

238 Data are presented as mean±SD unless otherwise indicated. All statistical analyses were carried out  
239 using SPSS software (Version 26) with significance for all analyses was set at  $p < 0.05$ . All outcome  
240 variables were first checked for normality and sphericity. The Greenhouse Geisser correction for the  
241 *F* statistic and related degrees of freedom was used when data violated sphericity. One-way ANOVA  
242 was used to compare changes over time with a main effect followed up with Bonferroni adjusted post  
243 hoc comparisons. For non-parametric data (e.g., RPE, TCOMF, TSENS) a Friedman test was used  
244 to compare variables over time, with significance followed up with Wilcoxon signed rank tests  
245 comparing each timepoint to baseline. Two-way ANOVA was used to compare changes over time (0  
246 vs. 6 h) and between control and heated limbs, with main and interaction effects followed up with  
247 Bonferroni adjusted post hoc comparisons. Peak change in mRNA and protein concentration was  
248 compared between control and heated limbs using paired sample T-tests. Pearson's correlation was  
249 performed between each of the peak and change of  $T_m$ ,  $T_{leg}$ , and the peak change of all genes of  
250 interest which demonstrated a significant difference.



251 **Results**

252 Physiological responses

253 The  $T_m$  displayed a main effect for group ( $f=35.7$ ,  $p=0.001$ ), time ( $f=88.1$ ,  $p<0.001$ ), and an interaction  
254 effect ( $f=82.9$ ,  $p<0.001$ ). No difference in  $T_m$  at was observed at baseline but as per design differences  
255 occurred between HEAT and CONT from 0.5 h until 4 h, as displayed in Figure 1. The  $T_m$  increased  
256 (from baseline  $34.7\pm 0.9^\circ\text{C}$ ) in HEAT from 0.5 h to 3 h but was unchanged in CONT (baseline  
257  $33.8\pm 1.5^\circ\text{C}$ ). Specifically, in HEAT  $T_m$  increased from baseline to  $37.6\pm 0.1^\circ\text{C}$  (after 1.5 h,  $p=0.007$ ),  
258 and  $38.1\pm 0.6^\circ\text{C}$  (3 h,  $p<0.001$ ), this equating to a change from baseline of  $3.0\pm 1.0^\circ\text{C}$  and  $3.5\pm 1.5^\circ\text{C}$   
259 respectively. Compared to CONT this was a  $+3.9\pm 1.2^\circ\text{C}$  and  $+5.2\pm 1.7^\circ\text{C}$  difference at 1.5 and 3 h  
260 ( $p<0.001$ ). The post intervention phase subsequently saw a reduction in temperature relative to the  
261 heating phase after 4 h whereby  $T_m$  at 6 h had returned to baseline and was not different between  
262 limbs ( $p=0.582$ ; CONT  $32.5\pm 1.6^\circ\text{C}$ , HEAT  $34.3\pm 1.2^\circ\text{C}$ ).

263

264 \*\*\*INSERT FIGURE 1 NEAR HERE PLEASE\*\*\*

265

266 The  $T_{leg}$  displayed a main effect for group ( $t=106.4$ ,  $p<0.001$ ), time ( $t=126.7$ ,  $p<0.001$ ), and an  
267 interaction effect ( $t=100.8$ ,  $p<0.001$ ).  $T_{leg}$  was greater in HEAT, from 0.5 h until 3 h (peak temperature  
268  $39.5\pm 1.0^\circ\text{C}$ ), and greater than CONT from 0.5 h onwards. Figure 1. A main effect of time was  
269 observed for  $T_{core}$  ( $t=4.8$ ,  $p=0.032$ ), and HR ( $t=6.3$ ,  $p=0.003$ ). Post hoc analysis did not identify a  
270 difference in  $T_{core}$  from baseline ( $37.3\pm 0.2^\circ\text{C}$ ) (Figure 1). Similarly, HR was unchanged from baseline  
271 (Table 2). TSENS reported a main effect for time ( $\chi^2=61.0$ ,  $p<0.001$ ) with post hoc differences from  
272 1 h until 3 h vs baseline (Table 2). In contrast, no statistical differences ( $p>0.05$ ) were observed in  
273  $T_{torso}$ ,  $\dot{Q}$ , MAP,  $\dot{V}O_2$ ,  $\dot{V}CO_2$ , RER,  $\dot{V}_E$ , [Glu], [Hb], Hct, RPE, TCOMF ( $p>0.05$ ). All physiological and  
274 perceptual data are presented in Table 2.

275

276 \*\*\*INSERT TABLE 2 NEAR HERE PLEASE\*\*\*

277

278 Gene responses over time in the heated limb

279 Increased gene expression was observed over the course of the HEAT intervention for eNOS ( $f=3.9$ ,  
280  $p=0.014$ ), Hsp72 ( $f=7.3$ ,  $p<0.001$ ), and VEGF $\alpha$  ( $f=3.7$ ,  $p=0.018$ ). Post hoc analyses identified that  
281 Hsp72 was higher at 4 h than baseline ( $p=0.048$ ;  $+5.2\pm 2.6$ -fold) (Figure 2). Post hoc differences could  
282 not be identified for eNOS and VEGF $\alpha$  (Figure 3). No effect ( $p>0.05$ ) was observed for ANGPT2,  
283 CCL2, FOXO1, HIF-1 $\alpha$ , Hsp27, Hsp60, Hsp90 $\alpha$ , VASH-1, VEGF $\alpha$ .

284

285 \*\*\*INSERT FIGURE 2 NEAR HERE PLEASE\*\*\*

286 \*\*\*INSERT FIGURE 3 NEAR HERE PLEASE\*\*\*

287

288 At 6 h, ANGPT-2 ( $f=7.8$ ,  $p=0.031$ ) was lower in HEAT than CONT, and VEGF $\alpha$  ( $f=8.0$ ,  $p=0.030$ ) was  
289 higher in HEAT than CONT, with no difference observed in any other genes at this end point of the  
290 protocol ( $p>0.05$ ).

291

#### 292 Gene responses between heated and control limb

293 When peak change during HEAT was calculated, ANGPT-2 reduced ( $-0.4\pm 0.2$ ;  $t=7.3$ ,  $p<0.001$ ), and  
294 CCL2 ( $2.9\pm 1.6$  fold;  $t=3.2$ ,  $p=0.019$ ), FOXO-1 ( $+6.2\pm 4.4$  fold;  $t=3.1$ ,  $p=0.021$ ), Hsp27 ( $+2.9\pm 1.7$  fold;  
295  $t=2.9$ ,  $p=0.029$ ), Hsp72 ( $+8.5\pm 3.5$  fold;  $t=5.7$ ,  $p=0.001$ ), Hsp90 $\alpha$  ( $+4.6\pm 3.7$  fold;  $t=2.5$ ,  $p=0.044$ ), and  
296 VEGF $\alpha$  ( $+5.9\pm 3.1$  fold;  $t=4.3$ ,  $p=0.005$ ) increased in comparison to baseline (Figure 4).

297

298 \*\*\*INSERT FIGURE 4 NEAR HERE PLEASE\*\*\*

299

300 Table 3 demonstrates the percentage of participants reporting a peak increase at each timepoint  
301 within HEAT and the average time to peak expression. Of the genes that demonstrated a change  
302 from baseline, 4 h and 6 h demonstrated the greatest number of instances where peak expression  
303 occurred. The ANGPT-2 peaked at  $2.1 \pm 0.8$  h, Hsp27 peaked at  $3.9 \pm 1.8$  h, Hsp72 peaked at  $4.8 \pm$   
304  $1.7$  h, and Hsp90 $\alpha$  peaked at  $4.5 \pm 1.9$  h. CCL2 (peak at  $3.9 \pm 1.6$  h), FOXO-1 (peak at  $3.3 \pm 1.6$  h)  
305 and VEGF (peak at  $3.7 \pm 1.9$  h) did not demonstrate a clear temporal response with individual  
306 participants reporting peaks across the full range of timepoints.

307

308 \*\*\*INSERT TABLE 3 NEAR HERE PLEASE\*\*\*

309

310 Peak change in HEAT was greater than the change in CONT for ANGPT-2 ( $t=3.9$ ,  $p=0.008$ ), FOXO-  
311 1 ( $t=2.9$ ,  $p=0.029$ ), Hsp72 ( $t=5.5$ ,  $p=0.002$ ), Hsp90 $\alpha$  ( $t=2.6$ ,  $p=0.042$ ), and VEGF $\alpha$  ( $t=4.1$ ,  $p=0.006$ ).  
312 There was no difference ( $p>0.05$ ) in CCL2, eNOS, HIF1 $\alpha$ , Hsp27, Hsp60, or VASH-1.

313

314 ANGPT2 demonstrated a relationship with change in  $T_{LEG}$  ( $r=0.839$ ,  $p=0.018$ ), and the peak change  
315 in Hsp72 demonstrated a relationship with FOXO1 ( $r=0.765$ ,  $p=0.045$ ), whilst VASH was related to  
316 Hsp27 ( $r=0.907$ ,  $p=0.005$ ). On the other hand, VEGF $\alpha$  demonstrated a relationship with eNOS  
317 ( $r=0.772$ ,  $p=0.042$ ), Hsp27 ( $r=0.821$ ,  $p=0.023$ ), and VASH ( $r=0.803$ ,  $p=0.030$ ).

318

#### 319 Protein responses

320 No change was observed in HSP72 concentration within the experimental limb during the five  
321 timepoints measured in HEAT ( $f=0.8$ ,  $p=0.522$ ). Additionally, when examining protein concentration  
322 at baseline and 6 h between CONT and HEAT, no main effect of group ( $f=0.5$ ,  $p=0.498$ ), time ( $f=0.3$ ,  
323  $p=0.594$ ), or interaction ( $f=0.0$ ,  $p=0.867$ ) was observed. The peak change in HSP72 protein following  
324 HEAT was not difference to CONT ( $t=2.3$ ,  $p=0.064$ ). Like HSP72 (Figure 5), no change was observed

325 in VEGF $\alpha$  concentration (n=6) during HEAT (f=4.7, p=0.072) or at baseline and 6 h between CONT  
326 and HEAT (group, f=0.8, p=0.409; time, f=3.6, p=0.115; interaction, f=4.8, p=0.081). The peak change  
327 in VEGF $\alpha$  protein following HEAT was different to CONT (t=3.5, p=0.018). Hsp72 mRNA  
328 demonstrated a relationship with HSP72 protein concentration at the 6 h timepoint (r=0.781, p=0.038).

329

330 \*\*\*INSERT FIGURE 5 NEAR HERE PLEASE\*\*\*

## 331 Discussion

332 The 3 h passive leg heating rapidly increased intramuscular (*vastus lateralis*) temperature,  $T_m$  being  
333 elevated by 3.0-3.5°C (+5°C vs contralateral limb) between 1.5 to 3 h and then declining progressively  
334 to baseline values by 6 h, with no or minimal systemic and contralateral leg physiological response.  
335 Peak skeletal muscle gene transcription was favourably altered from baseline in the heated limb for  
336 heat shock proteins (Hsp27, Hsp72, and Hsp90 $\alpha$ ) and regulatory genes (ANGPT-2, CCL2, FOXO-1,  
337 and VEGF $\alpha$ ). Examination of the time course of gene change eNOS, Hsp72, and VEGF $\alpha$  also  
338 demonstrated a change overall, however a timepoint specific change only occurred in Hsp72 at 4 h.  
339 Generally, the regulatory genes response which reported a change (i.e., ANGPT-2, CCL2, FOXO-1,  
340 and VEGF $\alpha$ ) peaked during or at the end of the 3 h heating period (peak expression at  $3.3 \pm 1.6$  h  
341 from baseline), with heat shock proteins (Hsp27, Hsp72, and Hsp90 $\alpha$ ) typically peaking during  
342 recovery (peak expression at  $4.4 \pm 1.8$  h from baseline). Only ANGPT-2 and VEGF $\alpha$  differed between  
343 CONT and HEAT at the end of the study (6 h) highlighting a general return to baseline of augmented  
344 genes following the cessation of local hyperthermia. Together these transcriptional responses  
345 highlight that interindividual differences exist in response to local passive hyperthermia, with an  
346 augmentation of gene response albeit at different timepoints (Table 3). The inconsistency in gene  
347 response, the implementation of acute thermal stimuli, and/or relatively short window of observation  
348 may explain the lack of change in HSP72 and VEGF $\alpha$  protein concentrations over the full timecourse  
349 of the protocol. As with peak gene responses, the calculation of peak change in VEGF $\alpha$  led to  
350 difference between limbs, this points to inter-individual protein responses to the same intervention.

351

### 352 Heat shock protein gene responses

353 The skeletal muscle heat shock protein gene response to passive heating has not been extensively  
354 considered with published data presenting conflicting findings. Early data by Morton et al. (50) did not  
355 demonstrate any change in mRNA expression of Hsp27, Hsp60, or Hsp70(50) by passive  
356 hyperthermia increasing core ( $+1.5^\circ\text{C}$  to  $38.9 \pm 0.2^\circ\text{C}$ ) and muscle temperatures ( $+3.6^\circ\text{C}$  to  
357  $39.5 \pm 0.2^\circ\text{C}$ ) via 1 h of one-legged hot water immersion. These data are therefore in conflict with our  
358 findings. On closer inspection of those experimental methods, the post biopsy sample was taken ~48  
359 h following heating, a time point when our Hsp time course data, and others(28), now indicate post-  
360 transcriptional concentrations would have returned to baseline. Following 90 min of local limb heating  
361 via water-perfused garments (without core temperature change), a 1.1-1.5-fold increase in Hsp27,  
362 Hsp60, Hsp72, and Hsp90 mRNA has been reported 30 min post heating(28). These data agree with  
363 the direction our findings (Figures 2 & 4). Within that experiment the comparison between only thigh  
364 heating, and lower body heating trials revealed no difference in the magnitude of change in gene  
365 response suggesting equivalent responses could be observed despite heating different tissue masses  
366 (and presumably eliciting subtly different muscle temperatures(26)). The absence of muscle  
367 temperature measurement does not allow a rigorous analysis of this hypothesis, however. A

368 comparison between single leg and whole-body heating (muscle temperatures= $38.1\pm 0.6^{\circ}\text{C}$  vs  
369  $38.8\pm 0.5^{\circ}\text{C}$ , core temperature= $37.1\pm 0.1^{\circ}\text{C}$  vs  $39.1\pm 0.3^{\circ}\text{C}$ ) saw increased Hsp25 (+50%), Hsp72  
370 (+362%) and Hsp90 (+64%) mRNA expression in whole body heating, but not in single leg  
371 heating(27). In that study authors concluded localized heating may be insufficient to increase Hsp  
372 gene expression when the duration and magnitude of the heat treatment is inadequate. Based on our  
373 correlation analysis timing of peak mRNA expression and subsequent gene degradation also poorly  
374 correlate with thermal response ( $T_m$ ) thus other factors appear relevant. Our data add to this  
375 conversation by demonstrating that for the same muscle temperature ( $\sim 38.1^{\circ}\text{C}$ ) an extended heating  
376 duration (rather than magnitude), causes similar increases in Hsp concentrations following single leg  
377 heating compared to whole body heating protocols. Our data, combined with animal studies (51), are  
378 indicative that absolute muscle temperature may not be critical in regulating the magnitude of Hsp  
379 mRNA response, however temperature range/increase in muscle temperature are potential factors in  
380 Hsp response once a  $\sim 37.6\text{-}38.1^{\circ}\text{C}$  muscle temperature threshold has been surpassed (for a  
381 sufficient duration). The time course of human HSP responses to interactions of heat and/or exercise  
382 not been well examined either. Using downhill running in the heat as a model for creating maximal  
383 skeletal muscle stress, it has been observed that both Hsp72 and Hsp90 $\alpha$  mRNA peak 30 min  
384 following exercise, with elevations persisting at 3 h post, but not 24 h post(52). Thirty minutes of  
385 exercise at the anaerobic threshold elicits equal increases in Hsp72 expression 30 min and 3 h  
386 following exercise(53), yet the timepoint of final decay was not characterised. Further, Hsp27 (+4-8-  
387 fold) and Hsp72 (+15-20-fold) increases are typically greatest and most prolonged when eccentric  
388 exercise is undertaken with significant peaking between 4 and 8 h following contractions with  
389 maintained mRNA expression 24 h later(54). Similar observations have been made in a strength  
390 training paradigm(55) though the timing of the myogenic gene induction is variable, peaking 4–8 h  
391 postexercise, with all gene expression returning to baseline after 24 h.

392

### 393 Angiogenic and regulatory gene responses

394 In addition to changes in Hsp expression our data also highlight that local hyperthermia is effective in  
395 positively modifying the expression of angiogenic regulatory genes, specifically ANGPT-2 which  
396 reduced, and CCL2, eNOS, and VEGF $\alpha$  which increased. This is in contrast to previous work by other  
397 groups, which suggested that single leg models were ineffective at inducing changes in gene  
398 expression(27). However, in agreement with our study, Kuhlenhoelter et al.,(28), demonstrated that  
399 leg hyperthermia increased VEGF $\alpha$  by  $\sim 1.5$  fold. Whilst CCL2 reduced in that experiment the  
400 reduction was attenuated relative to controls which may be considered analogous to our increase vs  
401 null control limb response(28). Regrettably in that study individual muscle temperatures and gene  
402 responses were not reported to confirm or refute the role this thermoregulatory variable has on  
403 individual responses a factor which limits interpretation of the magnitude and inter-individual range of  
404 response against our data. Understanding as to whether hyperthermia directly e.g., via temperature

405 sensing, or indirectly e.g., via shear stress(10, 56), induces mRNA signalling in heat therapy models  
406 remains equivocal and may be best assessed *ex vivo*. Given the central role that VEGF $\alpha$  plays in  
407 angiogenesis, including the influence on associated markers such as eNOS(57), examination of the  
408 time course of VEGF $\alpha$  expression is pertinent from a regulatory gene perspective. Sixty minutes of  
409 moderate intensity exercise elicits peak VEGF $\alpha$  increases (~4.5 fold) at 2 and 4 h post  
410 intervention(58), with a similar outcome when the duration (59) or intensity is increased (60).  
411 Prolonged two-legged knee extension exercise elicited increases in VEGF $\alpha$  mRNA 1.5 and 3 h after  
412 exercise onset, with the 9-fold increase peaking 1 h into recovery before returning to baseline after  
413 20 h. In comparison to these exercise protocols, our data demonstrate that passive heating can also  
414 induce increases in VEGF $\alpha$  albeit to a lesser degree than exercise of a similar duration(60). The  
415 difference in observed magnitude of response between passive heating and exercise models is  
416 perhaps unsurprising, given the difference in intensity of stimulus with heating delivering a lower  
417 'intensity' for the same duration. Nevertheless, passive heating induced changes in regulatory gene  
418 response are significant and have been shown to be sufficient to promote angiogenesis(17, 61). The  
419 observed relationships between genes e.g., the change in VEGF $\alpha$  and eNOS supports previous  
420 observations that VEGF receptor-2 upregulates eNOS and iNOS protein(57). The relationship  
421 between Hsp27 mRNA and VEGF $\alpha$  mRNA appears novel, however this is likely related to the VEGF-  
422 mediated cell migration and angiogenesis facilitated by HSP27, as demonstrated by work increasing  
423 extracellular concentrations via recombinant HSP27(62). Recently a study was undertaken to  
424 characterise the timecourse of changes in skeletal muscle regulatory gene expression in response to  
425 a session of high-intensity interval training(63) with the temporal pattern across the 23 genes of  
426 interest was highly variable (63). Both VEGF $\alpha$  and Hsp72 were included in the aforementioned  
427 analysis and demonstrated a peak change 9 h following exercise (Hsp72=+2.9-fold; VEGF $\alpha$  +1.3-  
428 fold), albeit with the change in VEGF $\alpha$  falling short of statistical significance. Hsp72 changes returned  
429 to baseline after 48 h. Exercise protocols therefore also show variable timeframes for peak gene  
430 expression and our data demonstrates that is now also evident in passive heating protocols. The  
431 variable peaking of expression also seems to align with the functional role of the gene(s). It is  
432 important to acknowledge that the variability in gene response during exercise protocols is expected  
433 given the various modes, durations, and intensity and the subsequent impact on cardiovascular,  
434 metabolic and temperature responses. It might be considered more unexpected that variability exists  
435 during passive heating given the relatively homogenous stimuli, with this having implications for how  
436 such intervention or treatment might be delivered. Taken together these acute increases in regulatory  
437 gene responses provide further support for vascular responses and adaptations to heat therapy. Our  
438 data are therefore supportive of the potential for heat therapy to serve as an alternative, precursor or  
439 complement to exercise training in those unwilling or unable to engage in physical activity, yet would  
440 benefit from vascular adaptation(2, 22, 23).

441

442 Protein responses

443 Though the HSP72 protein response to passive and exercise hyperthermia has been characterised  
444 in acutely extracellular fluid(4, 5, 37, 64–66), and at an intracellular level within circulating cells(34,  
445 67–74) few studies have examined the timecourse skeletal muscle response to hyperthermia. In  
446 support of our observation and previously discussed gene responses within skeletal muscle, Morton  
447 et al.,(50) reported no change in HSP72 48 h following passive heating. Further to this Kim et al.,(40)  
448 observing that passive heating following eccentric exercise did not alter HSP72 (and HSP90) protein  
449 concentration 24 h following treatment. Heating via shortwave diathermy has also elicited a null  
450 response in HSP72(18). These studies, and our data point towards a null response in HSP72  
451 intramuscular protein concentration following acute hyperthermia. A statistically significant, 45%  
452 increases in HSP72 following 2 h daily heating for 6 consecutive days(18), and +25% in response to  
453 2 hr daily heating during 10 days of limb immobilisation(20) highlighting the merits of chronic vs acute  
454 interventions. Our absence of changes over time in VEGF $\alpha$  protein concentration contrasts that of  
455 others who observed elevated VEGF $\alpha$  after one and five days of heat treatment following eccentric  
456 exercise(40). Interestingly the same group had previously observed that heating alone did not change  
457 VEGF $\alpha$  concentrations after four and eight weeks of treatment perhaps revealing context specific  
458 responses(17). Ambiguity in the acute VEGF $\alpha$  response in skeletal muscle has also been observed  
459 in exercise models(75), with some exercise studies observing increased concentrations(76–81) and  
460 others reporting null responses or decreases(58, 82). It is notable that despite our peak VEGF $\alpha$   
461 protein responses differing statistically between HEAT and CONT (irrespective of timepoint), intra-  
462 individual patterns of response point exist (Figure 5). This replicates the mRNA data within our study  
463 and the work of others(27), and published work examining protein content following acute exercise.

464

465 Methodological considerations and limitations

466 Given some previous work had created an equivocal picture of the relevance of a passive limb  
467 hyperthermia model, these data give reinforced credence to this method of local heat therapy and  
468 point to benefits arising from local applications that do not need to elicit systemic responses e.g.,  
469 elevated core temperature. It is unlikely that the duration of exposure utilised in this study would be  
470 well tolerated in using a whole-body heating protocol such as sauna or water immersion, therefore  
471 local heating provides an opportunity for the intervention to be applied for prolonged periods. The lack  
472 of distinction in gene response between 1.5 h and 3 h timepoints suggests that prolonging  
473 hyperthermia will not lead to a greater magnitude of gene response however there could be added  
474 benefit to having gene expression elevated for a longer duration per session. The homogenous  
475 intramuscular temperature responses across timepoints during the heating phase (Figure 1) but  
476 differing timepoints associated with a peak gene response, and interindividual range of gene  
477 responses (see Figure 2 and 3) suggest that heat therapy interventions might be more effectively  
478 implemented when prescribed at an individual level. The caveats to that statement being that at the

479 current time the optimal individualisation variable remains unknown and should be further  
480 investigated. It remains to be fully determined whether an equivalent intervention reporting a null  
481 response in young healthy individuals would elicit a positive outcome in patients e.g., those with  
482 vascular disease. Accordingly, future experimental consideration should also be given to the  
483 population studied i.e., like our data most experimental work to date has examined responses in  
484 young, healthy participants, rather than the prospective clinical population requiring treatment. Given  
485 that the clinical populations at which this therapy might be targeted are unlikely to be able to tolerate  
486 significant exercise protocols, passive heating is perhaps a more accessible treatment regimen, and  
487 one that causes negligible observed systemic perturbation even when implemented for prolonged  
488 durations (Table 2). Finally, to fully elucidate the role of muscle temperature on the magnitude of  
489 change in gene expression and protein concentration, further experimental work examining  
490 interactions between clamping muscle temperature at increasing magnitudes of local (skeletal  
491 muscle) hyperthermia (51, 83), across differing heating durations, is warranted.

492  
493 A limitation of this study is the lack of serial sampling of the control limb for changes in gene  
494 expression to confirm a null response throughout the intervention. With the exception of ANGPT-2  
495 and VEGF $\alpha$  which demonstrated a continued response following heating, the lack of difference  
496 between 0 h and 6 h measures in CONT for all other genes does however support the experimental  
497 design and highlights that the variability of measured gene expression does not explain the apparent  
498 differences among individuals. The absence of serial biopsy sampling in CONT also means that  
499 quantification of the potential effects of repeated biopsies during HEAT is not possible. Had these  
500 data been available in CONT, biological and methodological variability across the 3 h of heating and  
501 3 h of recovery could be quantified by subtracting the  $\Delta$ CONT from  $\Delta$ HEAT across timepoints.  
502 Nonetheless the delta between HEAT and CONT (Figure 4 and Figure 5) point to meaningful  
503 differences between interventions thus in spite of serial biopsy sampling in HEAT, a hyperthermi  
504 induced change above CONT was observed. Further to this, we acknowledge that whilst sufficient  
505 statistical power was observed for between leg comparisons and for some analyses (eNOS, Hsp72,  
506 VEGF $\alpha$ ,  $\eta$ p2 = 0.4-0.6), the observed power (0.55 – 0.76,  $\eta$ p2 = 0.3-0.4) for ANGPT-2, Hsp27,  
507 Hsp90 $\alpha$  indicates the study was underpowered for these genes. At a mechanistic level, circulating or  
508 systemic angiogenic mediators cannot be excluded from consideration as to beneficial factors arising  
509 from hyperthermia(11, 28, 84), nor can their influence on ANGPT-2 be discounted(85).

510

## 511 **Conclusion**

512 Prolonged (3 h) passive limb hyperthermia altered skeletal muscle ANGPT-2, CCL2, eNOS, FOXO-  
513 1, Hsp27, Hsp72, Hsp90 $\alpha$ , and VEGF $\alpha$  mRNA expression and increased the individual peak change  
514 in VEGF $\alpha$  protein concentration in healthy human participants, without modifying HSP72 protein  
515 concentration. Future applied and mechanistic work should acknowledge that angiogenic and heat



516 shock protein mRNA responses peak at different times between individuals undertaking passive limb  
517 hyperthermia protocols. It is unclear whether these differences impact the magnitude of adaptation if  
518 hyperthermia were to be repeated.

519

## 520 **Perspectives and Significance**

521 Prolonged passive leg hyperthermia transiently increases angiogenic mediators and heat shock  
522 proteins with minimal alterations in systemic or contralateral leg responses. These data point to the  
523 relevance of local mechanisms in augmenting ANGPT-2, CCL2, eNOS, FOXO-1, Hsp27, Hsp72,  
524 Hsp90 $\alpha$ , and VEGF $\alpha$  mRNA expression. Differing temporal patterns in gene response, and null  
525 protein responses point to a need to further understand relevant mRNA and protein kinetics during  
526 prolonged passive leg hyperthermia interventions.

527

## 528 **Acknowledgements**

529 The authors would like to thank Mr Tom Howes for his technical support during the experiment and  
530 Mr Nuno Koch Esteves for his assistance with data collection.

531

## 532 **Grants**

533 This study was jointly funded by The Physiological Society's 2017 Early Career Research Grant  
534 scheme, Brunel University London's Research Initiative and Enterprise Fund (BRIEF, 2017), and the  
535 Centre for Human Performance, Exercise and Rehabilitation (CHPER), Centre for Physical Activity in  
536 Health and Disease (CHPAD), at Brunel University London.

537

## 538 **Disclosures**

539 No conflicts of interest, financial or otherwise are declared by the authors.

540

## 541 **Author contributions**

542 ORG and JG-A conceived and design the experiment. ORG, RA, ZP, FNEG, JG-A performed the  
543 experiments. ORG analysed and illustrated the data. ORG, FNEG, and JG-A interpreted the results.  
544 ORG drafted the manuscript. ORG, RA, ZP, FNEG, JG-A edited and approved the final manuscript.

545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593

## References

1. **Brunt VE, Minson CT.** Heat therapy: mechanistic underpinnings and applications to cardiovascular health. *J Appl Physiol* 130: 1684–1704, 2021. doi: 10.1152/jappphysiol.00141.2020.
2. **Cheng JL, MacDonald MJ.** Effect of Heat Stress on Vascular Outcomes in Humans. *J Appl Physiol* 126: 771–781, 2019. doi: 10.1152/jappphysiol.00682.2018.
3. **Hesketh K, Shepherd SO, Strauss JA, Low DA, Cooper RG, Wagenmakers AJM, Cocks M.** Passive Heat Therapy in Sedentary Humans Increases Skeletal Muscle Capillarisation and eNOS Content but Not Mitochondrial Density or GLUT4 Content. *American Journal of Physiology-Heart and Circulatory Physiology* 317: H114–H123, 2019. doi: 10.1152/ajpheart.00816.2018.
4. **Hoekstra SP, Bishop NC, Faulkner SH, Bailey SJ, Leicht CA.** Acute and chronic effects of hot water immersion on inflammation and metabolism in sedentary, overweight adults. *J Appl Physiol* 125: 2008–2018, 2018. doi: 10.1152/jappphysiol.00407.2018.
5. **Hoekstra SP, Wright AKA, Bishop NC, Leicht CA.** The effect of temperature and heat shock protein 72 on the ex vivo acute inflammatory response in monocytes. *Cell Stress Chaperones* 24: 461–467, 2019. doi: 10.1007/s12192-019-00972-6.
6. **Leicht CA, James LJ, Briscoe JHB, Hoekstra SP.** Hot water immersion acutely increases postprandial glucose concentrations. *Physiol Rep* 7, 2019. doi: 10.14814/phy2.14223.
7. **Ely BR, Clayton ZS, McCurdy CE, Pfeiffer J, Needham KW, Comrada LN, Minson CT.** Heat therapy improves glucose tolerance and adipose tissue insulin signaling in obese women with polycystic ovary syndrome. *American Journal of Physiology-Endocrinology and Metabolism* 317: E172–E182, 2019. doi: 10.1152/ajpendo.00549.2018.
8. **Ely BR, Francisco MA, Halliwill JR, Bryan SD, Comrada LN, Larson EA, Brunt VE, Minson CT.** Heat therapy reduces sympathetic activity and improves cardiovascular risk profile in obese women with polycystic ovary syndrome. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* 317: R630–R640, 2019. doi: 10.1152/ajpregu.00078.2019.
9. **Brunt VE, Eymann TM, Francisco MA, Howard MJ, Minson CT.** Passive heat therapy improves cutaneous microvascular function in sedentary humans via improved nitric oxide-dependent dilation. *J Appl Physiol* 121: 716–723, 2016. doi: 10.1152/jappphysiol.00424.2016.
10. **Brunt VE, Howard MJ, Francisco MA, Ely BR, Minson CT.** Passive heat therapy improves endothelial function, arterial stiffness, and blood pressure in sedentary humans. *J Physiol* 0: 1–14, 2016. doi: 10.1113/JP272453.
11. **Brunt VE, Weidenfeld-Needham KM, Comrada LN, Francisco MA, Eymann TM, Minson CT.** Serum from young, sedentary adults who underwent passive heat therapy improves endothelial cell angiogenesis via improved nitric oxide bioavailability. *Temperature* 16: 23328940.2019.1614851, 2019. doi: 10.1080/23328940.2019.1614851.
12. **Park S-Y, Kwak Y-S, Pekas EJ.** Impacts of aquatic walking on arterial stiffness, exercise tolerance, and physical function in patients with peripheral artery disease: a randomized clinical trial. *J Appl Physiol* 127: 940–949, 2019. doi: 10.1152/jappphysiol.00209.2019.
13. **Imamura M, Biro S, Kihara T, Yoshifuku S, Takasaki K, Otsuji Y, Minagoe S, Toyama Y, Tei C.** Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. *J Am Coll Cardiol* 38: 1083–8, 2001.
14. **Neff D, Kuhlenhoelter AM, Lin C, Wong BJ, Motaganahalli RL, Roseguini BT.** Thermo-therapy reduces blood pressure and circulating endothelin-1 concentration and enhances leg blood flow in patients with symptomatic peripheral artery disease. *American*


- 594 *Journal of Physiology-Regulatory, Integrative and Comparative Physiology* 311: R392–R400,  
 595 2016. doi: 10.1152/ajpregu.00147.2016.
- 596 15. **Pizzey FK, Smith EC, Ruediger SL, Keating SE, Askew CD, Coombes JS, Bailey TG.**  
 597 The effect of heat therapy on blood pressure and peripheral vascular function: A systematic  
 598 review and meta-analysis. *Exp Physiol* 106: 1317–1334, 2021. doi: 10.1113/EP089424.
- 599 16. **Akerman AP, Thomas KN, van Rij AM, Body ED, Alfadhel M, Cotter JD.** Heat therapy  
 600 vs. supervised exercise therapy for peripheral arterial disease: a 12-week randomized,  
 601 controlled trial. *American Journal of Physiology-Heart and Circulatory Physiology* 316:  
 602 H1495–H1506, 2019. doi: 10.1152/ajpheart.00151.2019.
- 603 17. **Kim K, Reid BA, Casey CA, Bender BE, Ro B, Song Q, Trewin AJ, Petersen AC, Kuang  
 604 S, Gavin TP, Roseguini BT.** Effects of repeated local heat therapy on skeletal muscle  
 605 structure and function in humans. *J Appl Physiol* 128: 483–492, 2020. doi:  
 606 10.1152/jappphysiol.00701.2019.
- 607 18. **Hafen PS, Preece CN, Sorensen JR, Hancock CR, Hyldahl RD.** Repeated exposure to heat  
 608 stress induces mitochondrial adaptation in human skeletal muscle. *J Appl Physiol* 125: 1447–  
 609 1455, 2018. doi: 10.1152/jappphysiol.00383.2018.
- 610 19. **Pellinger TK, Neighbors CB, Simmons GH.** Acute Lower Leg Heating Increases Exercise  
 611 Capacity in Patients With Peripheral Artery Disease. *Journal of Cardiovascular Nursing* 34:  
 612 130–133, 2019. doi: 10.1097/JCN.0000000000000510.
- 613 20. **Hafen PS, Abbott K, Bowden J, Lopiano R, Hancock CR, Hyldahl RD.** Daily heat  
 614 treatment maintains mitochondrial function and attenuates atrophy in human skeletal muscle  
 615 subjected to immobilization. *J Appl Physiol* 127: 47–57, 2019. doi:  
 616 10.1152/jappphysiol.01098.2018.
- 617 21. **Racinais S, Wilson MG, Périard JD.** Passive heat acclimation improves skeletal muscle  
 618 contractility in humans. *Am J Physiol Regul Integr Comp Physiol* 312: R101–R107, 2017. doi:  
 619 10.1152/ajpregu.00431.2016.
- 620 22. **Hunt AP, Minett GM, Gibson OR, Kerr GK, Stewart IB.** Could Heat Therapy Be an  
 621 Effective Treatment for Alzheimer’s and Parkinson’s Diseases? A Narrative Review. *Front  
 622 Physiol* 10: 1556, 2020. doi: 10.3389/fphys.2019.01556.
- 623 23. **Ely BR, Clayton ZS, McCurdy CE, Pfeiffer J, Minson CT.** Meta-inflammation and  
 624 cardiometabolic disease in obesity: Can heat therapy help? *Temperature* 5: 9–21, 2018. doi:  
 625 10.1080/23328940.2017.1384089.
- 626 24. **Chiesa ST, Trangmar SJ, Kalsi KK, Rakobowchuk M, Banker DS, Lotlikar MD, Ali L,  
 627 González-Alonso J.** Local temperature-sensitive mechanisms are important mediators of limb  
 628 tissue hyperemia in the heat-stressed human at rest and during small muscle mass exercise.  
 629 *American Journal of Physiology-Heart and Circulatory Physiology* 309: H369–H380, 2015.  
 630 doi: 10.1152/ajpheart.00078.2015.
- 631 25. **Cheng JL, Williams JS, Hoekstra SP, MacDonald MJ.** Improvements in vascular function  
 632 in response to acute lower limb heating in young healthy males and females. *J Appl Physiol*  
 633 131: 277–289, 2021. doi: 10.1152/JAPPLPHYSIOL.00630.2020.
- 634 26. **Koch Esteves N, Gibson Oliver R, Khir A, González-Alonso J.** Regional thermal hyperemia  
 635 in the human leg: Evidence of the importance of thermosensitive mechanisms in the control of  
 636 the peripheral circulation. *Physiol Rep* 9: e14953, 2021. doi: 10.14814/PHY2.14953.
- 637 27. **Ihsan M, Deldicque L, Molphy J, Britto F, Cherif A, Racinais S.** Skeletal Muscle  
 638 Signaling Following Whole-Body and Localized Heat Exposure in Humans. *Front Physiol* 11:  
 639 839, 2020. doi: 10.3389/fphys.2020.00839.
- 640 28. **Kuhlenhoelter AM, Kim K, Neff D, Nie Y, Blaize AN, Wong BJ, Kuang S, Stout J, Song  
 641 Q, Gavin TP, Roseguini BT.** Heat therapy promotes the expression of angiogenic regulators  
 642 in human skeletal muscle. *Am J Physiol Regul Integr Comp Physiol* 311: R377–91, 2016. doi:  
 643 10.1152/ajpregu.00134.2016.

- 644 29. **Wilhelm EN, González-Alonso J, Chiesa ST, Trangmar SJ, Kalsi KK, Rakobowchuk M.**  
645 Whole-body heat stress and exercise stimulate the appearance of platelet microvesicles in  
646 plasma with limited influence of vascular shear stress. *Physiol Rep* 5: e13496, 2017. doi:  
647 10.14814/phy2.13496.
- 648 30. **Goto K, Oda H, Kondo H, Igaki M, Suzuki A, Tsuchiya S, Murase T, Hase T, Fujiya H,**  
649 **Matsumoto I, Naito H, Sugiura T, Ohira Y, Yoshioka T.** Responses of muscle mass,  
650 strength and gene transcripts to long-term heat stress in healthy human subjects. *Eur J Appl*  
651 *Physiol* 111: 17–27, 2011. doi: 10.1007/s00421-010-1617-1.
- 652 31. **Cullen T, Clarke ND, Hill M, Menzies C, Pugh CJA, Steward CJ, Thake CD.** The health  
653 benefits of passive heating and aerobic exercise: To what extent do the mechanisms overlap? *J*  
654 *Appl Physiol* 129: 1304–1309, 2020. doi: 10.1152/JAPPLPHYSIOL.00608.2020.
- 655 32. **Henstridge DC, Febbraio MA, Hargreaves M.** Heat shock proteins and exercise  
656 adaptations. Our knowledge thus far and the road still ahead. *J Appl Physiol* 120: 683–691,  
657 2016. doi: 10.1152/jappphysiol.00811.2015.
- 658 33. **Gibson OR, Turner Gareth, Tuttle JAlexander, Taylor Lee, Watt PW, Maxwell NS.** Heat  
659 acclimation attenuates physiological strain and the HSP72, but not HSP90 $\alpha$ , mRNA response  
660 to acute normobaric hypoxia. *J Appl Physiol (1985)* 119: 889–99, 2015. doi:  
661 10.1152/jappphysiol.00332.2015.
- 662 34. **Magalhães FDC, Amorim FT, Passos RLF, Fonseca MA, Oliveira KPM, Lima MRM,**  
663 **Guimarães JB, Ferreira-Júnior JB, Martini ARP, Lima NR v, Soares DD, Oliveira EM,**  
664 **Rodrigues LOC.** Heat and exercise acclimation increases intracellular levels of Hsp72 and  
665 inhibits exercise-induced increase in intracellular and plasma Hsp72 in humans. *Cell Stress*  
666 *Chaperones* 15: 885–95, 2010. doi: 10.1007/s12192-010-0197-7.
- 667 35. **Liu Y, Mayr S, Opitz-Gress A, Zeller C, Lormes W, Baur S, Lehmann M, Steinacker**  
668 **JM.** Human skeletal muscle HSP70 response to training in highly trained rowers. [Online]. *J*  
669 *Appl Physiol* 86: 101–4, 1999. <http://www.ncbi.nlm.nih.gov/pubmed/9887119>.
- 670 36. **Morton JP, Maclaren DPM, Cable NT, Campbell IT, Evans L, Kayani AC, McArdle A,**  
671 **Drust B.** Trained men display increased basal heat shock protein content of skeletal muscle.  
672 *Med Sci Sports Exerc* 40: 1255–62, 2008. doi: 10.1249/MSS.0b013e31816a7171.
- 673 37. **Gibson OR, Dennis A, Parfitt T, Taylor L, Watt PW, Maxwell NS.** Extracellular Hsp72  
674 concentration relates to a minimum endogenous criteria during acute exercise-heat exposure.  
675 *Cell Stress Chaperones* 19: 389–400, 2014. doi: 10.1007/s12192-013-0468-1.
- 676 38. **Mee JA, Gibson OR, Tuttle JA, Taylor L, Watt PW, Doust J, Maxwell NS.** Leukocyte  
677 Hsp72 mRNA transcription does not differ between males and females during heat  
678 acclimation. *Temperature* 3: 549–556, 2016.
- 679 39. **Gibson OR, Mee JA, Taylor L, Tuttle JA, Watt PW, Maxwell NS.** Isothermic and fixed-  
680 intensity heat acclimation methods elicit equal increases in Hsp72 mRNA. *Scand J Med Sci*  
681 *Sports* 25: 259–268, 2015. doi: 10.1111/sms.12430.
- 682 40. **Kim K, Kuang S, Song Q, Gavin TP, Roseguini BT.** Impact of heat therapy on recovery  
683 following eccentric exercise in humans. .
- 684 41. **Sawka MN, Burke LM, Eichner ER, Maughan RJ, Montain SJ, Stachenfeld NS.**  
685 American College of Sports Medicine position stand. Exercise and fluid replacement.  
686 *Medicine and Science in Sport and Exercise* 39: 377–90, 2007. doi:  
687 10.1249/mss.0b013e31802ca597.
- 688 42. **Chiesa ST, Trangmar SJ, González-Alonso J.** Temperature and blood flow distribution in  
689 the human leg during passive heat stress. *J Appl Physiol* 120: 1047–58, 2016. doi:  
690 10.1152/jappphysiol.00965.2015.
- 691 43. **Pearson J, Kalsi KK, Stöhr EJ, Low DA, Barker H, Ali L, González-Alonso J.**  
692 Haemodynamic responses to dehydration in the resting and exercising human leg. *Eur J Appl*  
693 *Physiol* 113: 1499–1509, 2013. doi: 10.1007/s00421-012-2579-2.

- 694 44. **Jones PR, Pearson J.** Anthropometric determination of leg fat and muscle plus bone volumes  
695 in young male and female adults. [Online]. *Journal of Physiology* 204: 63P-66P, 1969.  
696 <http://www.ncbi.nlm.nih.gov/pubmed/5824654> [23 May 2018].
- 697 45. **Wesseling KH, Jansen JR, Settels JJ, Schreuder JJ.** Computation of aortic flow from  
698 pressure in humans using a nonlinear, three-element model. *J Appl Physiol* 74: 2566–2573,  
699 1993. doi: 10.1152/jappl.1993.74.5.2566.
- 700 46. **Toner MM, Drolet LL, Pandolf KB.** Perceptual and physiological responses during exercise  
701 in cool and cold water. [Online]. *Percept Mot Skills* 62: 211–20, 1986.  
702 <http://www.ncbi.nlm.nih.gov/pubmed/3960662> [11 Feb. 2014].
- 703 47. **Borg GA.** Psychophysical bases of perceived exertion. [Online]. *Medicine and Science in*  
704 *Sport and Exercise* 14: 377–81, 1982. <http://www.ncbi.nlm.nih.gov/pubmed/7154893> [1 Jul.  
705 2016].
- 706 48. **MacInnis MJ, McGlory C, Gibala MJ, Phillips SM.** Investigating human skeletal muscle  
707 physiology with unilateral exercise models: when one limb is more powerful than two.  
708 *Applied Physiology, Nutrition, and Metabolism* 42: 563–570, 2017. doi: 10.1139/apnm-2016-  
709 0645.
- 710 49. **Tarnopolsky MA, Pearce E, Smith K, Lach B.** Suction-modified Bergström muscle biopsy  
711 technique: experience with 13,500 procedures. *Muscle Nerve* 43: 717–25, 2011. doi:  
712 10.1002/mus.21945.
- 713 50. **Morton JP, Maclaren DPM, Cable NT, Campbell IT, Evans L, Bongers T, Griffiths RD,  
714 Kayani a C, McArdle a, Drust B.** Elevated core and muscle temperature to levels  
715 comparable to exercise do not increase heat shock protein content of skeletal muscle of  
716 physically active men. *Acta Physiol (Oxf)* 190: 319–27, 2007. doi: 10.1111/j.1748-  
717 1716.2007.01711.x.
- 718 51. **Kim K, Reid BA, Ro B, Casey CA, Song Q, Kuang S, Roseguini BT.** Heat therapy  
719 improves soleus muscle force in a model of ischemia-induced muscle damage. *J Appl Physiol*  
720 127: 215–228, 2019. doi: 10.1152/jappphysiol.00115.2019.
- 721 52. **Tuttle JA, Christmas BCR, Gibson OR, Barrington JH, Hughes DC, Castle PC, Metcalfe  
722 AJ, Midgley AW, Pearce O, Kabir C, Rayanmarakar F, Al-Ali S, Lewis MP, Taylor L.**  
723 The Hsp72 and Hsp90a mRNA responses to hot downhill running are reduced following a  
724 prior bout of hot downhill running, and occur concurrently within leukocytes and the vastus  
725 lateralis. *Front Physiol* 8, 2017. doi: 10.3389/fphys.2017.00473.
- 726 53. **Puntschart A, Vogt M, Widmer HR, Hoppeler H, Billeter R.** Hsp70 expression in human  
727 skeletal muscle after exercise. *Acta Physiol Scand* 157: 411–7, 1996. doi: 10.1046/j.1365-  
728 201X.1996.512270000.x.
- 729 54. **Paulsen G, Vissing K, Magne Kalhovde J, Ugelstad I, Lucia Bayer M, Kadi F, Schjerling  
730 P, Hallén J, Raastad T.** Maximal eccentric exercise induces a rapid accumulation of small  
731 heat shock proteins on myofibrils and a delayed HSP70 response in humans. *Am J Physiol*  
732 *Regul Integr Comp Physiol* 293: 844–853, 2007. doi: 10.1152/ajpregu.00677.2006.-In.
- 733 55. **Yang Y, Creer A, Jemiolo B, Trappe S.** Time course of myogenic and metabolic gene  
734 expression in response to acute exercise in human skeletal muscle. *J Appl Physiol* 98: 1745–  
735 1752, 2005. doi: doi: 10.1152/jappphysiol.01185.2004.
- 736 56. **Caldwell AR, Robinson FB, Tucker MA, Arcement CH, Butts CL, McDermott BP,  
737 Ganio MS.** Effect of passive heat stress and exercise in the heat on arterial stiffness. .
- 738 57. **Kroll J, Waltenberger J.** VEGF-A induces expression of eNOS and iNOS in endothelial  
739 cells via VEGF receptor-2 (KDR). *Biochem Biophys Res Commun* 252: 743–746, 1998. doi:  
740 10.1006/bbrc.1998.9719.
- 741 58. **Gavin TP, Robinson CB, Yeager RC, England JA, Nifong LW, Hickner RC.** Angiogenic  
742 growth factor response to acute systemic exercise in human skeletal muscle. *J Appl Physiol*  
743 96: 19–24, 2004. doi: doi: 10.1152/jappphysiol.00748.2003.



- 744 59. **Hoier B, Prats C, Qvortrup K, Pilegaard H, Bangsbo J, Hellsten Y.** Subcellular  
745 localization and mechanism of secretion of vascular endothelial growth factor in human  
746 skeletal muscle. *The FASEB Journal* 27: 3496–3504, 2013. doi: 10.1096/FJ.12-224618.
- 747 60. **Hiscock N, Fischer CP, Pilegaard H, Pedersen BK.** Vascular endothelial growth factor  
748 mRNA expression and arteriovenous balance in response to prolonged, submaximal exercise  
749 in humans. *Am J Physiol Heart Circ Physiol* 285: H1759-63, 2003. doi:  
750 10.1152/AJPHEART.00150.2003.
- 751 61. **Hesketh K, Shepherd SO, Strauss JA, Low DA, Cooper RG, Wagenmakers AJM, Cocks  
752 M.** Passive Heat Therapy in Sedentary Humans Increases Skeletal Muscle Capillarisation and  
753 eNOS Content but Not Mitochondrial Density or GLUT4 Content. .
- 754 62. **Thuringer D, Jegu G, Wettstein G, Terrier O, Cronier L, Yousfi N, Hébrard S, Bouchot  
755 A, Hazoumé A, Joly A-L, Gleave M, Rosa-Calatrava M, Solary E, Garrido C.**  
756 Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3. *FASEB J* 27: 4169–  
757 4183, 2013. doi: 10.1096/fj.12-226977.
- 758 63. **Kuang J, McGinley C, Lee MJ-C, Saner NJ, Garnham A, Bishop DJ.** Interpretation of  
759 exercise-induced changes in human skeletal muscle mRNA expression depends on the timing  
760 of the post-exercise biopsies. .
- 761 64. **Périard JD, Ruell P, Caillaud C, Thompson MW.** Plasma Hsp72 (HSPA1A) and Hsp27  
762 (HSPB1) expression under heat stress: influence of exercise intensity. *Cell Stress Chaperones*  
763 17: 375–83, 2012. doi: 10.1007/s12192-011-0313-3.
- 764 65. **Faulkner SH, Jackson S, Fatania G, Leicht CA.** The effect of passive heating on heat shock  
765 protein 70 and interleukin-6: A possible treatment tool for metabolic diseases? .
- 766 66. **Taylor L, Lee BJ, Gibson OR, Midgley AW, Watt P, Mauger A, Castle P.** Effective  
767 microorganism – X attenuates circulating superoxide dismutase following an acute bout of  
768 intermittent running in hot, humid conditions. .
- 769 67. **Behzadi P, Ravanelli N, Gravel H, Barry H, Debray A, Chaseling GK, Jacquemet V,  
770 Neagoe P-E, Nigam A, Carpentier AC, Sirois MG, Gagnon D.** Acute effect of passive heat  
771 exposure on markers of cardiometabolic function in adults with type 2 diabetes mellitus. *J*  
772 *Appl Physiol* 132: 1154–1166, 2022. doi: 10.1152/jappphysiol.00800.2021.
- 773 68. **Amorim F, Yamada P, Robergs R, Schneider S, Moseley P.** Effects of whole-body heat  
774 acclimation on cell injury and cytokine responses in peripheral blood mononuclear cells. *Eur J*  
775 *Appl Physiol* 111: 1609–18, 2011. doi: 10.1007/s00421-010-1780-4.
- 776 69. **Hom LL, Lee EC-H, Apicella JM, Wallace SD, Emmanuel H, Klau JF, Poh PYS,  
777 Marzano S, Armstrong LE, Casa DJ, Maresh CM.** Eleven days of moderate exercise and  
778 heat exposure induces acclimation without significant HSP70 and apoptosis responses of  
779 lymphocytes in college-aged males. *Cell Stress Chaperones* 17: 29–39, 2012. doi:  
780 10.1007/s12192-011-0283-5.
- 781 70. **Kuennen M, Gillum T, Dokladny K, Bedrick E, Schneider S, Moseley P.** Thermotolerance  
782 and heat acclimation may share a common mechanism in humans. *Am J Physiol Regul Integr*  
783 *Comp Physiol* 301: R524-33, 2011. doi: 10.1152/ajpregu.00039.2011.
- 784 71. **Lee BJ, Miller A, James RS, Thake CD.** Cross acclimation between heat and hypoxia: Heat  
785 acclimation improves cellular tolerance and exercise performance in acute normobaric  
786 hypoxia. *Front Physiol* 7:78, 2016. doi: 10.3389/fphys.2016.00078.
- 787 72. **Marshall HC, Campbell SA, Roberts CW, Nimmo MA.** Human physiological and heat  
788 shock protein 72 adaptations during the initial phase of humid-heat acclimation. *J Therm Biol*  
789 32: 341–348, 2007. doi: 10.1016/j.jtherbio.2007.04.003.
- 790 73. **McClung JP, Hasday JD, He J-RR, Montain SJ, Chevront SN, Sawka MN, Singh IS.**  
791 Exercise-heat acclimation in humans alters baseline levels and ex vivo heat inducibility of  
792 HSP72 and HSP90 in peripheral blood mononuclear cells. *Am J Physiol Regul Integr Comp*  
793 *Physiol* 294: R185-91, 2008. doi: 10.1152/ajpregu.00532.2007.

- 794 74. **Maloyan A, Palmon A, Horowitz M, Tetievsky A, Cohen O, Eli-berchoer L, Gerstenblith**  
795 **G, Stern MD, Mclung JP, Hasday JD, He J, Montain SJ, Chevront SN, Sawka N,**  
796 **Singh IS, Melling CWJ, Thorp DB, Milne KJ, Krause MP, Noble EG, Horo- M.** Heat  
797 acclimation increases the basal HSP72 level and alters its production dynamics during heat  
798 stress memory. .
- 799 75. **Hoier B, Hellsten Y.** Exercise-Induced Capillary Growth in Human Skeletal Muscle and the  
800 Dynamics of VEGF. *Microcirculation* 21: 301–314, 2014. doi: 10.1111/MICC.12117.
- 801 76. **Gavin TP, Drew JL, Kubik CJ, Pofahl WE, Hickner RC.** Acute resistance exercise  
802 increases skeletal muscle angiogenic growth factor expression. *Acta Physiologica* 191: 139–  
803 146, 2007. doi: <https://doi.org/10.1111/j.1748-1716.2007.01723.x>.
- 804 77. **Hoier B, Nordsborg N, Andersen S, Jensen L, Nybo L, Bangsbo J, Hellsten Y.** Pro- and  
805 anti-angiogenic factors in human skeletal muscle in response to acute exercise and training. *J*  
806 *Physiol* 590: 595–606, 2012. doi: <https://doi.org/10.1113/jphysiol.2011.216135>.
- 807 78. **Gavin TP, Ruster RS, Carrithers JA, Zwetsloot KA, Kraus RM, Evans CA, Knapp DJ,**  
808 **Drew JL, McCartney JS, Garry JP, Hickner RC.** No difference in the skeletal muscle  
809 angiogenic response to aerobic exercise training between young and aged men. *J Physiol* 585:  
810 231–239, 2007. doi: <https://doi.org/10.1113/jphysiol.2007.143198>.
- 811 79. **Hoier B, Passos M, Bangsbo J, Hellsten Y.** Intense intermittent exercise provides weak  
812 stimulus for vascular endothelial growth factor secretion and capillary growth in skeletal  
813 muscle. *Exp Physiol* 98: 585–597, 2013. doi: <https://doi.org/10.1113/expphysiol.2012.067967>.
- 814 80. **Hoier B, Walker M, Passos M, Walker PJ, Green A, Bangsbo J, Askew CD, Hellsten Y.**  
815 Angiogenic response to passive movement and active exercise in individuals with peripheral  
816 arterial disease. *J Appl Physiol* 115: 1777–1787, 2013. doi: 10.1152/japplphysiol.00979.2013.
- 817 81. **Rullman E, Rundqvist H, Wågsäter D, Fischer H, Eriksson P, Sundberg CJ, Jansson E,**  
818 **Gustafsson T.** A single bout of exercise activates matrix metalloproteinase in human skeletal  
819 muscle. *J Appl Physiol* 102: 2346–2351, 2007. doi: 10.1152/japplphysiol.00822.2006.
- 820 82. **Hoier B, Prats C, Qvortrup K, Pilegaard H, Bangsbo J, Hellsten Y.** Subcellular  
821 localization and mechanism of secretion of vascular endothelial growth factor in human  
822 skeletal muscle. *The FASEB Journal* 27: 3496–3504, 2013. doi: [https://doi.org/10.1096/fj.12-](https://doi.org/10.1096/fj.12-224618)  
823 [224618](https://doi.org/10.1096/fj.12-224618).
- 824 83. **Blake MJ, Gershon D, Fagnoli J, Holbrook NJ.** Discordant expression of heat shock  
825 protein mRNAs in tissues of heat-stressed rats. *Journal of Biological Chemistry* 265: 15275–  
826 15279, 1990. doi: 10.1016/S0021-9258(18)77252-9.
- 827 84. **Neff D, Kuhlenhoelter AM, Lin C, Wong BJ, Motaganahalli RL, Roseguini BT.**  
828 Thermo-therapy reduces blood pressure and circulating endothelin-1 concentration and  
829 enhances leg blood flow in patients with symptomatic peripheral artery disease. *American*  
830 *Journal of Physiology-Regulatory, Integrative and Comparative Physiology* 311: R392–R400,  
831 2016. doi: 10.1152/ajpregu.00147.2016.
- 832 85. **Akwii RG, Sajib MS, Zahra FT, Mikelis CM.** Role of Angiopoietin-2 in Vascular  
833 Physiology and Pathophysiology. *Cells* 8: 471, 2019. doi: 10.3390/cells8050471.
- 834  
835




838  
839 **Figure 1.** Muscle temperature ( $T_m$ , circles), leg skin temperature ( $T_{leg}$ , squares), and core temperature  
840 ( $T_{core}$ , triangles,  $p > 0.05$  from baseline). Data are presented as Mean $\pm$ SD ( $n = 7$ ). BL=baseline. \*  
841 denotes difference from BL, † denotes difference from CONT. Blue represents CONT, red represents  
842 HEAT.  
843  
844  
845






846  
 847 **Figure 2.** Heat shock protein gene responses over time for HEAT (red bars) and CONT (blue bars)  
 848 limbs. Individual data points are colour coded for each participant with squares representing female  
 849 participants. Data are presented as Mean±SD (n=7). \* denotes a main effect for time within gene  
 850 (p<0.05). # denotes identified post hoc difference within HEAT (p<0.05).  
 851




852  
853  
854  
855  
856  
857

**Figure 3.** Regulatory gene responses over time for HEAT (red bars) and CONT (blue bars). Individual data points are colour coded for each participant with squares representing female participants. Data are presented as Mean±SD (n=7). \* denotes a main effect for time within gene (p<0.05). + denotes difference between HEAT and CONT at 6 h timepoint.



858  
859  
860  
861  
862  
863

**Figure 4.** Peak change in selected gene responses over time for HEAT (red bars) and CONT (blue bars) limbs. Individual data points are colour coded for each participant with squares representing female participants. Data are presented as Mean $\pm$ SD (n=7). \* denotes a difference from baseline within trial ( $p < 0.05$ ). † denotes a difference from CONT within HEAT ( $p < 0.05$ ).



864  
 865 **Figure 5.** HSP72 (n = 7) and VEGFα (n = 6) protein concentration over time for HEAT (red bars) and  
 866 CONT (blue bars). Insert figure represents peak change. Individual data points are colour coded for  
 867 each participant with squares representing female participants. Data are presented as Mean±SD for  
 868 6-7 participants. \* denotes a difference from CONT within HEAT (p<0.05)  
 869

## Tables and legends

**Table 1.** List of genes included in the analysis

Full name	Gene abbreviation	Gene symbol	Aliases	Primers [Forward (F) & Reverse (R)]	Role(s)
<b>Heat shock protein genes</b>					
Heat shock protein family B (small) member 1	Hsp27	HSPB1	CMT2F, HEL-S-102, HMN2B, HS.76067, HSP27, HSP28, Hsp25, SRP27	F: CACGAGGAGCGGCAGGACGAG R: CAGTGGCGGCAGCAGGGTGG	Chaperone activity, inhibition of apoptosis, regulation of cell and differentiation.
Heat shock protein family D (Hsp60) member 1	Hsp60	HSPD1	CPN60, GROEL, HLD4, HSP-60, HSP60, HSP65, HuCHA60, SPG13	F: GATGTCCTGGGCTGTTTCAT R: GCCTCGATCAAACCTTCATGC	Prevention of protein misfolding
Heat shock protein family A (Hsp70) member 1A	Hsp72	HSPA1A	HEL-S-103, HSP70-1, HSP70-1A, HSP70.1, HSP70I, HSP72, HSPA1	F: GGTGCTGACCAAGATGAAG R: CTGCGAGTCGTTGAAGTAG	Correct folding of new or misfolded proteins. DNA repair. Induction of pro-inflammatory cytokines
Heat shock protein 90 alpha family class A member 1	Hsp90 $\alpha$	HSP90AA1	EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, Hsp89, Hsp90, LAP-2, LAP2	F: ATCAAACCTGGTCTGGGTATT R: GATGTGTCGTCATCTCCTTC	Protein folding, maintenance, and degradation. Intracellular transport. Cell signaling.
<b>Regulatory genes</b>					
Angiotensin 2	ANGPT-2	ANGPT2	AGPT2, ANG2	F: TGGACAATTATTCAGCGACGTG R: GCTGGTCGGATCATCATGGTTG	A member of the angiotensin family of growth factors, an antagonist of angiotensin-1 in blood vasculature.
C-C motif chemokine ligand 2	CCL2	CCL2	GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1, SCYA2, SMC-CF	F: AGAATCACCAGCAGCAAGTGTCC R: TCCTGAACCCACTTCTGCTTGG	Myokine with role in skeletal muscle remodelling including angiogenesis
Nitric oxide synthase 3	eNOS	NOS3	ECNOS, eNOS	F: ACCCTCACCGCTACAACATC R: CTGGCCTTCTGCTCATTCTC	Maintenance of endothelial homeostasis via generation of nitric oxide in the vascular endothelium
Forkhead box O1	FOXO-1	FOXO1	FKH1, FKHR, FOXO1A	F: CTACGAGTGGATGGTCAAGAGC R: CCAGTTCCTTCACTTCTGCACAG	Regulates angiostatic factors, restraining angiogenesis.
Glyceraldehyde-3-phosphate dehydrogenase	GAPDH	GAPDH	G3PD, GAPD, HEL-S-162eP	F: AATCCCATCACCATCTTCCA R: TGGACTCCACGACGTACTCA	Control for this experiment. Functional role in energy metabolism and the production of ATP and pyruvate through anaerobic glycolysis in the cytoplasm
Hypoxia inducible factor 1 alpha subunit	HIF-1 $\alpha$	HIF1A	HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1, PASD8, bHLHe78	F: CTAGCCGGAGGAAGAACTATGAAC R: CCCACACTGAGGTTGGTACTGT	Master regulator of vascular responses, driving transcriptional activation of genes involved in vascular reactivity and angiogenesis.
Vasohibin 1	VASH1	VASH1	KIAA1036	F: ATGGACCTGGCCAAGGAAAT R: CATCCTTCTCCGGTCTTG	Angiogenesis inhibitor expressed in endothelial cells via induction by pro-angiogenesis factors

Vascular endothelial growth factor A	VEGF $\alpha$	VEGFA	MVCD1, VEGF, VPF	F: TTTCTGCTGTCTTGGGTGCATTGG R: ACCACTTCGTGATGATTCTGCCCT	Regulates angiogenesis by inducing proliferation, migration, and permeability of endothelial cells.
--------------------------------------	---------------	-------	------------------	--	---

**Table 2.** Physiological and perceptual responses during the protocol.

	Time (h)						
	Baseline	1	2	3	4	5	6
<b>HR</b> (b.min <sup>-1</sup> )	64 ± 15	72 ± 15	71 ± 13	75 ± 18	65 ± 13	63 ± 13	68 ± 17
<b>Q̇</b> (L·min <sup>-1</sup> )	6.1 ± 1.6	6.8 ± 1.1	6.6 ± 1.2	7.0 ± 1.3	6.3 ± 1.7	6.1 ± 1.8	6.8 ± 1.5
<b>MAP</b> (mmHg)	87 ± 9	79 ± 6	84 ± 8	86 ± 9	89 ± 15	88 ± 19	89 ± 12
<b>ṠO<sub>2</sub></b> (L·min <sup>-1</sup> )	0.29 ± 0.07	0.33 ± 0.08	0.35 ± 0.06	0.35 ± 0.05	0.35 ± 0.05	0.34 ± 0.04	0.34 ± 0.04
<b>Ṡ<sub>E</sub></b> (L·min <sup>-1</sup> )	8 ± 2	9 ± 2	8 ± 2	9 ± 1	8 ± 1	8 ± 2	9 ± 1
<b>T<sub>torso</sub></b> (°C)	32.9 ± 1.3	33.4 ± 1.3	32.6 ± 1.8	32.7 ± 1.7	33.0 ± 1.5	33.4 ± 1.1	33.1 ± 1.6
<b>[Glu]</b> (mmol·L <sup>-1</sup> )	5.5 ± 0.5	-	-	5.3 ± 0.4	5.5 ± 0.8	-	5.3 ± 0.6
<b>[Hb]</b> (g·L <sup>-1</sup> )	148 ± 11	143 ± 13	144 ± 11	147 ± 14	146 ± 12	145 ± 12	146 ± 10
<b>Hct</b> (%)	45.4 ± 3.1	44.5 ± 3.2	44.9 ± 3.4	44.9 ± 3.3	45.4 ± 3.1	45.2 ± 3.2	46.1 ± 2.6
<b>RPE</b>	6 ± 0	6 ± 0	6 ± 0	6 ± 1	7 ± 1	7 ± 2	7 ± 2
<b>TSENS</b>	3.8 ± 0.4	5.1 ± 0.6 *	5.4 ± 0.9 *	5.5 ± 1.1 *	3.7 ± 0.4	3.6 ± 0.4	3.7 ± 0.4
<b>TCOMF</b>	1 ± 1	1 ± 1	2 ± 1	1 ± 1	1 ± 0	1 ± 0	1 ± 0

Data are mean $\pm$ SD (n=7). \* denotes difference vs 0 h (Baseline) (p<0.05). HR: heart rate,  $\dot{Q}$ : cardiac output, MAP: mean arterial pressure,  $\dot{V}O_2$ : oxygen consumption,  $\dot{V}_E$ : minute ventilation,  $T_{\text{torso}}$ : Torso temperature, [Glu]: blood glucose concentration, [Hb]: haemoglobin concentration, Hct: haematocrit, RPE: rating of perceived exertion, TSENS: thermal sensation, TCOMF: thermal comfort.

**Table 3.** Frequency of peak gene response for each sample timepoint during the 3 h leg heating protocol and subsequent 3 h recovery.

	1.5 h	3 h	4 h	6 h	Time to peak (h)
<b>Heat shock protein genes</b>					
<b>Hsp27 *</b>	29%	0%	<b>43%</b>	29%	<b>3.9 ± 1.8</b>
Hsp60	<b>43%</b>	<b>43%</b>	0%	14%	2.8 ± 1.6
<b>Hsp72 *</b>	14%	0%	29%	<b>57%</b>	<b>4.8 ± 1.7</b>
<b>Hsp90α *</b>	14%	29%	0%	<b>57%</b>	<b>4.5 ± 1.9</b>
<b>Regulatory genes</b>					
<b>ANGPT-2 *</b>	<b>57%</b>	43%	0%	0%	<b>2.1 ± 0.8</b>
<b>CCL2 *</b>	14%	<b>29%</b>	<b>29%</b>	<b>29%</b>	<b>3.9 ± 1.6</b>
eNOS	0%	<b>71%</b>	14%	14%	3.1 ± 1.8
<b>FOXO-1 *</b>	<b>29%</b>	<b>29%</b>	<b>29%</b>	14%	<b>3.3 ± 1.6</b>
HIF-1a	14%	<b>57%</b>	0%	29%	3.6 ± 1.7
VASH-1	14%	<b>29%</b>	<b>29%</b>	<b>29%</b>	3.9 ± 1.6
<b>VEGFα *</b>	<b>29%</b>	14%	<b>29%</b>	<b>29%</b>	<b>3.7 ± 1.9</b>

\* denotes a significant peak change vs baseline (p<0.05). Time to peak reported at mean ± SD. Bold text in cell denotes timepoint(s) corresponding to greatest proportion of peak gene changes